Meiwe Biopharmaceuticals: Signs a licensing agreement with Kalexo worth up to $1 billion.

Maiwei Bio announced that the company has signed an "Exclusive License Agreement" and a "Preferred Stock Purchase Agreement" with Kalexo, authorizing Kalexo to exclusively develop, manufacture, and commercialize the 2MW7141 project globally. Maiwei Bio will receive a total of up to $1 billion in upfront payments and milestone payments from Kalexo, as well as a low single-digit royalty fee. The agreement includes a non-refundable upfront payment and a near-term payment of $12 million. Additionally, Maiwei Bio will receive a double-digit total of Series A preferred shares from Kalexo under agreed conditions. The signing of the agreement is expected to have a positive impact on the company's future performance and profitability.